Back to top

earnings-consensus: Archive

Zacks Equity Research

Wall Street Analysts See a 34.27% Upside in Ezcorp (EZPW): Can the Stock Really Move This High?

The mean of analysts' price targets for Ezcorp (EZPW) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

EZPWPositive Net Change

Zacks Equity Research

Nvidia (NVDA) Reports Next Week: Wall Street Expects Earnings Growth

Nvidia (NVDA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NVDANegative Net Change

Zacks Equity Research

Urban Outfitters (URBN) Earnings Expected to Grow: Should You Buy?

Urban Outfitters (URBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

URBNNegative Net Change

Zacks Equity Research

The Cooper Companies (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COOPositive Net Change

Zacks Equity Research

Analysts Estimate Kohl's (KSS) to Report a Decline in Earnings: What to Look Out for

Kohl's (KSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KSSPositive Net Change

Zacks Equity Research

Smucker (SJM) Expected to Beat Earnings Estimates: Should You Buy?

Smucker (SJM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SJMPositive Net Change

Zacks Equity Research

Five Below (FIVE) Earnings Expected to Grow: Should You Buy?

Five Below (FIVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FIVENegative Net Change

Zacks Equity Research

Royal Bank (RY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Royal Bank (RY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RYPositive Net Change BNSPositive Net Change

Zacks Equity Research

Abercrombie & Fitch (ANF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Abercrombie (ANF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANFNegative Net Change

Zacks Equity Research

How Much Upside is Left in JBS N.V. (JBS)? Wall Street Analysts Think 41.82%

The mean of analysts' price targets for JBS N.V. (JBS) points to a 41.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

JBSNegative Net Change

Zacks Equity Research

Earnings Preview: PVH (PVH) Q2 Earnings Expected to Decline

PVH (PVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PVHPositive Net Change

Zacks Equity Research

nCino (NCNO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

nCino (NCNO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NCNOPositive Net Change VNETNegative Net Change

Zacks Equity Research

Bank of Nova Scotia (BNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Bank of Nova Scotia (BNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BNSPositive Net Change

Zacks Equity Research

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?

The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

DMACPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 25.38% Upside in Perpetua Resources (PPTA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in Perpetua Resources (PPTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PPTAPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Tyra Biosciences (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TYRAPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ALGSNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Dutch Bros (BROS) Could Surge 26.73%: Read This Before Placing a Bet

The consensus price target hints at a 26.7% upside potential for Dutch Bros (BROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BROSNegative Net Change

Zacks Equity Research

Heico Corporation (HEI) Earnings Expected to Grow: Should You Buy?

Heico (HEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HEIPositive Net Change

Zacks Equity Research

Earnings Preview: PDD Holdings Inc. Sponsored ADR (PDD) Q2 Earnings Expected to Decline

PDD Holdings Inc. Sponsored ADR (PDD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PDDNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

RAPTPositive Net Change

Zacks Equity Research

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

XOMAPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MLYSNegative Net Change

Zacks Equity Research

Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade

The consensus price target hints at a 26.7% upside potential for Kiniksa Pharmaceuticals International, plc (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

KNSAPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Brainsway (BWAY) Could Surge 25.58%: Read This Before Placing a Bet

The mean of analysts' price targets for Brainsway (BWAY) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BWAYPositive Net Change